OXFORD, England, March 8, 2012 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy

OXFORD, England, September 27, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive phase II clinical

OXFORD, England, June 13, 2011 /PRNewswire/ -- - Results Presented at Plenary Symposium of European Academy of Allergy and Clinical Immunology Congress - Cat Allergy T-cell Vaccine to Begin Phase III Testing in H1 2012 Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune(R) cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

OXFORD, England, April 19, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has closed a GBP60 million ($98 million) fundraising.

OXFORD, England, February 9, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales. PAP-1 is one of the most potent and selective Kv1.3 inhibitors known, and has ideal topical delivery characteristics.